{"id":450571,"date":"2021-03-04T08:03:36","date_gmt":"2021-03-04T13:03:36","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=450571"},"modified":"2021-03-04T08:03:36","modified_gmt":"2021-03-04T13:03:36","slug":"accolade-completes-acquisition-of-2nd-md","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/accolade-completes-acquisition-of-2nd-md\/","title":{"rendered":"Accolade Completes Acquisition of 2nd.MD"},"content":{"rendered":"

\nThe combination brings together advocacy, benefits navigation, and expert medical opinion to elevate the member experience by creating the most comprehensive, integrated healthcare navigation experience.
\n<\/h2>\n
\n

SEATTLE, March 04, 2021 (GLOBE NEWSWIRE) — Accolade, Inc. (Nasdaq: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate and utilize the healthcare system and their workplace benefits, today announced it has completed the acquisition of Innovation Specialists, LLC d\/b\/a 2nd.MD. By combining the market leaders in benefit navigation, health advocacy, and expert medical opinion services, Accolade will deliver the most comprehensive healthcare navigation experience covering more than 400 customers and 9 million lives.<\/p>\n

\u201cBoth Accolade and 2nd.MD share a vision to help every person live their healthiest life through a people-focused, clinically-driven support model. Together we can dramatically improve the quality and accessibility of care while helping employees navigate the increasingly complex healthcare system,\u201d said Rajeev Singh, chief executive officer, Accolade. \u201cIn addition to the expanded services and clinical capabilities we will be able to offer our customers, 2nd.MD brings new industry distribution relationships to help grow our business and expands our addressable market by an estimated $22 billion.\u201d<\/p>\n

Pursuant to the merger agreement previously announced on January 14, 2021, the transaction is valued at up to $460 million, consisting of $230 million in cash and $130 million in Accolade common stock from the issuance of approximately 2.8 million shares to be registered for resale in a registration statement via Form S-1, and up to $100 million in Accolade common stock from the issuance of approximately 2.1 million shares upon the achievement of defined revenue milestones. Accolade intends to provide guidance for the combined company when it reports it financial results for the fourth quarter and fiscal year 2021.<\/p>\n

\n About Accolade<\/strong>\n <\/p>\n

Accolade provides personalized health and benefits solutions designed to empower every person to live their healthiest life. Accolade helps millions of people and their employers navigate the complexities of the healthcare system with empathy, expertise and through exceptional service while supporting them in lowering the cost of care and improving health outcomes. Accolade blends technology-enabled health and benefits solutions, specialized support from Accolade Health Assistants\u00ae and Clinicians and access to expert medical opinion services for high-cost treatment decisions. Accolade consistently receives consumer satisfaction ratings over 90 percent. For more information, visit Accolade on LinkedIn, Twitter, Instagram and Facebook and at www.accolade.com.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth and our financial outlook. Forward-looking statements are subject to risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance. In some cases, you can identify forward-looking statements because they contain words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201clikely,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould,\u201d or similar expressions and the negatives of those terms.<\/p>\n

Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) risks associated with (a) the failure to complete or receive the anticipated benefits from the transaction, including due to Accolade\u2019s inability to successfully integrate 2nd.MD into its business, (b) diverting management attention from ongoing business operations, (c) the commencement or outcome of any legal proceedings that may be instituted against us or 2nd.MD in connection with the transaction and (d) the effects of the transaction on the combined business, including on operating costs, customer loss and business disruption; (ii) changes in laws and regulations applicable to our or 2nd.MD\u2019s business model; (iii) changes in market or industry conditions, regulatory environment and receptivity to our or 2nd.MD\u2019s technology and services; (iv) results of litigation or a security incident; (v) the loss of one or more of our or 2nd.MD\u2019s key customers or partners; (vi) the impact of COVID-19 on our or 2nd.MD\u2019s business and results of operation; (vii) changes to our or 2nd.MD\u2019s abilities to recruit and retain qualified team members; and the risks described in the other filings Accolade makes with the Securities and Exchange Commission from time to time, including the risks described under the heading \u201cRisk Factors\u201d in Accolade\u2019s most recently filed Quarterly Report on Form 10-Q, which should be read in conjunction with its financial results and forward-looking statements. All forward-looking statements in this press release are based on information available to Accolade as of the date hereof, and it does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.<\/p>\n

\n Investor Contact:<\/strong>\n <\/p>\n

Todd Friedman, Investor Relations, 484-532-5200, Todd.Friedman@accolade.com<\/a><\/p>\n

Asher Dewhurst, Investor Relations, 443-213-0500, Accolade@westwicke.com<\/a><\/p>\n

\n Media Contact:<\/strong>\n <\/p>\n

Megan Torres, Public Relations, 206-926-8180, Megan.Torres@accolade.com<\/a><\/p>\n

Source: Accolade<\/p>\n

A photo accompanying this announcement is available at https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/3737bfe9-0a4d-41c8-bdee-aaed50980551<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

The combination brings together advocacy, benefits navigation, and expert medical opinion to elevate the member experience by creating the most comprehensive, integrated healthcare navigation experience. SEATTLE, March 04, 2021 (GLOBE NEWSWIRE) — Accolade, Inc. (Nasdaq: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate and utilize the healthcare system and their workplace benefits, today announced it has completed the acquisition of Innovation Specialists, LLC d\/b\/a 2nd.MD. By combining the market leaders in benefit navigation, health advocacy, and expert medical opinion services, Accolade will deliver the most comprehensive healthcare navigation experience covering more than 400 customers and 9 million lives. \u201cBoth Accolade and 2nd.MD share a vision to help every person live their healthiest life through a people-focused, … <\/p>\n

Continue reading “Accolade Completes Acquisition of 2nd.MD”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-450571","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAccolade Completes Acquisition of 2nd.MD - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/accolade-completes-acquisition-of-2nd-md\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Accolade Completes Acquisition of 2nd.MD - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"The combination brings together advocacy, benefits navigation, and expert medical opinion to elevate the member experience by creating the most comprehensive, integrated healthcare navigation experience. SEATTLE, March 04, 2021 (GLOBE NEWSWIRE) — Accolade, Inc. (Nasdaq: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate and utilize the healthcare system and their workplace benefits, today announced it has completed the acquisition of Innovation Specialists, LLC d\/b\/a 2nd.MD. By combining the market leaders in benefit navigation, health advocacy, and expert medical opinion services, Accolade will deliver the most comprehensive healthcare navigation experience covering more than 400 customers and 9 million lives. \u201cBoth Accolade and 2nd.MD share a vision to help every person live their healthiest life through a people-focused, … Continue reading "Accolade Completes Acquisition of 2nd.MD"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/accolade-completes-acquisition-of-2nd-md\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-04T13:03:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ4NiM0MDQ3NzkyIzIxOTQ1MTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/accolade-completes-acquisition-of-2nd-md\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/accolade-completes-acquisition-of-2nd-md\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Accolade Completes Acquisition of 2nd.MD\",\"datePublished\":\"2021-03-04T13:03:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/accolade-completes-acquisition-of-2nd-md\\\/\"},\"wordCount\":903,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/accolade-completes-acquisition-of-2nd-md\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDQ4NiM0MDQ3NzkyIzIxOTQ1MTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/accolade-completes-acquisition-of-2nd-md\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/accolade-completes-acquisition-of-2nd-md\\\/\",\"name\":\"Accolade Completes Acquisition of 2nd.MD - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/accolade-completes-acquisition-of-2nd-md\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/accolade-completes-acquisition-of-2nd-md\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDQ4NiM0MDQ3NzkyIzIxOTQ1MTY=\",\"datePublished\":\"2021-03-04T13:03:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/accolade-completes-acquisition-of-2nd-md\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/accolade-completes-acquisition-of-2nd-md\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/accolade-completes-acquisition-of-2nd-md\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDQ4NiM0MDQ3NzkyIzIxOTQ1MTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDQ4NiM0MDQ3NzkyIzIxOTQ1MTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/accolade-completes-acquisition-of-2nd-md\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Accolade Completes Acquisition of 2nd.MD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Accolade Completes Acquisition of 2nd.MD - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/accolade-completes-acquisition-of-2nd-md\/","og_locale":"en_US","og_type":"article","og_title":"Accolade Completes Acquisition of 2nd.MD - Market Newsdesk","og_description":"The combination brings together advocacy, benefits navigation, and expert medical opinion to elevate the member experience by creating the most comprehensive, integrated healthcare navigation experience. SEATTLE, March 04, 2021 (GLOBE NEWSWIRE) — Accolade, Inc. (Nasdaq: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate and utilize the healthcare system and their workplace benefits, today announced it has completed the acquisition of Innovation Specialists, LLC d\/b\/a 2nd.MD. By combining the market leaders in benefit navigation, health advocacy, and expert medical opinion services, Accolade will deliver the most comprehensive healthcare navigation experience covering more than 400 customers and 9 million lives. \u201cBoth Accolade and 2nd.MD share a vision to help every person live their healthiest life through a people-focused, … Continue reading \"Accolade Completes Acquisition of 2nd.MD\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/accolade-completes-acquisition-of-2nd-md\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-04T13:03:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ4NiM0MDQ3NzkyIzIxOTQ1MTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/accolade-completes-acquisition-of-2nd-md\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/accolade-completes-acquisition-of-2nd-md\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Accolade Completes Acquisition of 2nd.MD","datePublished":"2021-03-04T13:03:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/accolade-completes-acquisition-of-2nd-md\/"},"wordCount":903,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/accolade-completes-acquisition-of-2nd-md\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ4NiM0MDQ3NzkyIzIxOTQ1MTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/accolade-completes-acquisition-of-2nd-md\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/accolade-completes-acquisition-of-2nd-md\/","name":"Accolade Completes Acquisition of 2nd.MD - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/accolade-completes-acquisition-of-2nd-md\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/accolade-completes-acquisition-of-2nd-md\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ4NiM0MDQ3NzkyIzIxOTQ1MTY=","datePublished":"2021-03-04T13:03:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/accolade-completes-acquisition-of-2nd-md\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/accolade-completes-acquisition-of-2nd-md\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/accolade-completes-acquisition-of-2nd-md\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ4NiM0MDQ3NzkyIzIxOTQ1MTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ4NiM0MDQ3NzkyIzIxOTQ1MTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/accolade-completes-acquisition-of-2nd-md\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Accolade Completes Acquisition of 2nd.MD"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/450571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=450571"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/450571\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=450571"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=450571"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=450571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}